StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Buy Rating on Amylyx Pharmaceuticals inc. (AMLX)
March 25, 2026 6:57 AM
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $34.00 price target on Amylyx Pharmaceuticals inc. (NASDAQ: AMLX).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
